PYFLAZ Trademark

Trademark Overview

On Friday, May 12, 2017, a trademark application was filed for PYFLAZ with the United States Patent and Trademark Office. The USPTO has given the PYFLAZ trademark a serial number of 79211285. The federal status of this trademark filing is REGISTERED as of Tuesday, June 12, 2018. This trademark is owned by Idorsia Pharmaceuticals Ltd.. The PYFLAZ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for cardiovascular, pulmonary, inflammatory indications as well as for the treatment of cancer
pyflaz

General Information

Serial Number79211285
Word MarkPYFLAZ
Filing DateFriday, May 12, 2017
Status700 - REGISTERED
Status DateTuesday, June 12, 2018
Registration Number5488747
Registration DateTuesday, June 12, 2018
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 27, 2018

Trademark Statements

Goods and ServicesPharmaceutical preparations for cardiovascular, pulmonary, inflammatory indications as well as for the treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, July 7, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameIdorsia Pharmaceuticals Ltd.
Party Type30 - Original Registrant
Legal Entity Type25 - NOT AVAILABLE
AddressCH
Party NameIdorsia Pharmaceuticals Ltd.
Party Type20 - Owner at Publication
Legal Entity Type25 - NOT AVAILABLE
AddressCH
Party NameIdorsia Pharmaceuticals Ltd.
Party Type10 - Original Applicant
Legal Entity Type25 - NOT AVAILABLE
AddressCH

Trademark Events

Event DateEvent Description
Monday, June 12, 2023COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, February 26, 2021NEW REPRESENTATIVE AT IB RECEIVED
Friday, October 12, 2018FINAL DECISION TRANSACTION PROCESSED BY IB
Thursday, September 20, 2018FINAL DISPOSITION NOTICE SENT TO IB
Thursday, September 20, 2018FINAL DISPOSITION PROCESSED
Wednesday, September 12, 2018FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, June 12, 2018REGISTERED-PRINCIPAL REGISTER
Tuesday, March 27, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 27, 2018PUBLISHED FOR OPPOSITION
Saturday, March 24, 2018NOTIFICATION PROCESSED BY IB
Wednesday, March 7, 2018NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, March 7, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 7, 2018NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Thursday, February 22, 2018ASSIGNED TO LIE
Monday, February 12, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, February 8, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 7, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, February 7, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, February 7, 2018ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, February 7, 2018TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, December 21, 2017NEW REPRESENTATIVE AT IB RECEIVED
Friday, September 1, 2017REFUSAL PROCESSED BY IB
Thursday, August 17, 2017NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, August 17, 2017REFUSAL PROCESSED BY MPU
Wednesday, August 16, 2017NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, August 15, 2017NON-FINAL ACTION WRITTEN
Thursday, August 10, 2017ASSIGNED TO EXAMINER
Tuesday, July 11, 2017APPLICATION FILING RECEIPT MAILED
Friday, July 7, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 6, 2017SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

pyflaz well treatment cancer indications inflammatory preparations cardiovascular pulmonary pharmaceutical